Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01872689 · ClinicalTrials.gov registry record · Phase 2
A Study of Lebrikizumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)
A Phase 2 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 2
- Development phase
- 505
- Enrollment target
NCT01872689 is a Phase 2 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 505 participants.
The verdict
NCT01872689, a Phase 2 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 505 participants
- Enrollment target
Study Summary
This randomized, multicenter, double-blind, placebo-controlled, parallel-group study will evaluate the efficacy and safety of lebrikizumab as monotherapy in the absence of background IPF therapy and as combination therapy with pirfenidone background therapy in participants with IPF. Participants will be randomized to receive either lebrikizumab or placebo subcutaneously every 4 weeks.
Interventions
- DRUG Placebo
- DRUG Lebrikizumab
- DRUG Pirfenidone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 505 participants |
| Start Date | 2013-10-13 |
| Est. Completion | 2017-11-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01872689
The ClinicalTrials.gov registry entry for NCT01872689 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 505 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01872689 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01872689 about?
NCT01872689 is a clinical study titled "A Study of Lebrikizumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)". This randomized, multicenter, double-blind, placebo-controlled, parallel-group study will evaluate the efficacy and safety of lebrikizumab as monotherapy in the absence of background IPF therapy and as combination therapy with pirfenidone background therapy in participants with IPF. Participants wil...
What is the current status of trial NCT01872689?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 505 participants. The study started on 2013-10-13. Estimated completion is 2017-11-06.
What interventions are being tested in trial NCT01872689?
The interventions under investigation include: Placebo (DRUG), Lebrikizumab (DRUG), Pirfenidone (DRUG).
Who is sponsoring clinical trial NCT01872689?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.